“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...
In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...
The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the ...
News-Medical.Net on MSN
UT Southwestern performs first regional whole liver chemotherapy for rare eye cancer
A team at UT Southwestern Medical Center this week became the first in Texas and neighboring states to successfully perform a novel procedure to deliver whole-liver chemotherapy to treat metastatic ...
Metastasis and disease progression remain the leading causes of mortality in both breast and cervical cancer. These processes ...
In this global network study, researchers examined vitamin B12 levels as a possible biomarker for outcomes in colon cancer.
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for ...
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results